Skip to main content
Clinical Trials/NCT05752630
NCT05752630
Recruiting
Not Applicable

The Relation Between Physical Activity, Sedentary Behaviour, and Cardiometabolic Health in Multiple Sclerosis

Hasselt University1 site in 1 country50 target enrollmentJanuary 30, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis, Relapsing-Remitting
Sponsor
Hasselt University
Enrollment
50
Locations
1
Primary Endpoint
Waist circumference
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

This study evaluates the association between sedentary behaviour, physical activity, and the cardiometabolic health of Multiple Sclerosis via several cardiovascular, metabolic and anthropometric parameters.

Detailed Description

Multiple sclerosis (MS) is an autoimmune, inflammatory and neurodegenerative disorder of the central nervous system, predominantly affecting young to middle-aged adults. The disease manifests in a broad spectrum of associated sensory, motor and psychological dysfunction, and there is a large variability in symptoms between (and within) persons with MS (PwMS). This can (partly) be explained by the co-existence of cardiometabolic (CM) diseases, such as hypertension, dyslipidaemia, insulin resistance or diabetes. More specifically, the presence of one or more of these CM diseases has been associated with a worsening of disability, independent of the timing of their development (at MS symptom onset, diagnosis, or later in the disease course). Therefore, the prevention and/or treatment of these CM comorbidities also warrant attention in MS rehabilitation. In most studies PwMS and HC were matched on age, sex, height and weight. Importantly, differences in physical activity (PA) and sedentary behaviour (SB) were never taken into account, while this might be a relevant matching risk factor between groups. Moreover, Ranadive et al. found a significant worse vascular function in PwMS compared to HC, but differences were accounted for by low PA in PwMS. This might mean that PwMS can completely attenuate their increased CM risk by increasing their PA. However, this conclusion was only based on a statistical correction, there was a large difference in PA between groups and other confounding factors (such as PA intensity, smoking and nutrition intake) were not taken into account. Therefore, the present study aims to investigate the relation between CM health and different intensities of PA and SB in PA-matched PwMS and HC. When CM health is comparable between PwMS and HC with similar PA levels, this shows the importance of including PA and SB measures and interventions as early as possible in MS treatment before automatically starting CM medication because PwMS are known to have multiple risk factors.

Registry
clinicaltrials.gov
Start Date
January 30, 2023
End Date
January 20, 2024
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hasselt University
Responsible Party
Principal Investigator
Principal Investigator

Bert Op't Eijnde

Principal Investigator

Hasselt University

Eligibility Criteria

Inclusion Criteria

  • Relapse-remitting MS
  • 25-60 years old
  • EDSS \< 5
  • Sedentary behaviour (\>9hours daily)

Exclusion Criteria

  • \<9h SB/day,
  • experienced an acute exacerbation within 6 months before the start of the study
  • an expanded disability status scale (EDSS) score \>5
  • experimental drug use or medication changes in the last month
  • medical conditions precluding PA participation
  • alcohol abuse (\>20 units/week)
  • reported dietary habits or weight loss (\>2kg) in the last month before the study
  • intention to start a new specific diet or start to follow an exercise intervention
  • reported participation in another biomedical trial which may have an effect on blood parameters 1 month before the start of the study
  • blood donation in the past month

Outcomes

Primary Outcomes

Waist circumference

Time Frame: After 7 days of physical activity monitoring

Waist circumference will be measured to the nearest 0.1cm using a flexible metric measuring tape with participants barefoot (in underwear) in standing position. Waist circumference is measured at the midpoint between the lower rib margin and the top of the iliac crest.

Hip circumference

Time Frame: After 7 days of physical activity monitoring

Hip circumference will be measured to the nearest 0.1cm using a flexible metric measuring tape with participants barefoot (in underwear) in standing position. Hip circumference is measured at the widest circumference of the hip at the level of the greater trochanter.

Concentration of total cholesterol

Time Frame: After 7 days of physical activity monitoring

Blood analysis

Concentration of low density lipoprotein cholesterol (LDL-cholesterol)

Time Frame: After 7 days of physical activity monitoring

Blood analysis

Respiratory gas exchange ratio (RER)

Time Frame: After 7 days of physical activity monitoring

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis RER is collected breath-by-breath and averaged every ten seconds.

Concentration of Insulin

Time Frame: After 7 days of physical activity monitoring

Blood analysis of insulin during OGTT

Concentration of high density lipoprotein cholesterol (HDL-cholesterol

Time Frame: After 7 days of physical activity monitoring

Blood analysis

metabolic syndrome (MetS) risk score

Time Frame: After 7 days of physical activity monitoring

A continuous metabolic syndrome risk score will be calculated using the waist circumference, HDL concentration, systolic blood pressure, triglycerides and fasting glucose levels, as described by Gurka et al. (2014). A higher score indicates worse health. Because this is a continuous scale, there is no minimum and maximum value.

Body weight

Time Frame: After 7 days of physical activity monitoring

Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1 kg

Height

Time Frame: After 7 days of physical activity monitoring

Body height is measured to the nearest 0.1cm using a wall-mounted Harpenden stadiometer, with participants barefoot

DEXA (Dual Energy X-Ray)

Time Frame: After 7 days of physical activity monitoring

body fat mass and lean tissue mass using Dual Energy X-ray Absorptiometry

Concentration of glucose

Time Frame: After 7 days of physical activity monitoring

Concentration of glucose measured in blood analysis during OGTT

Concentration of triglyceride

Time Frame: After 7 days of physical activity monitoring

Blood analysis

Concentration of inflammatory markers

Time Frame: After 7 days of physical activity monitoring

blood analysis of IL-6, TNF-α and C-reactive protein

Reactive hyperaemia index (RHI)

Time Frame: After 7 days of physical activity monitoring

Vascular endothelial function will be assessed by non-invasive peripheral arterial tonometry using the EndoPAT™ 2000 device. The reactive hyperaemia index reflects the reactive hyperaemia response, and is calculated as the ratio of the average peripheral arterial tone (PAT) signal in the posthyperemic phase to the baseline PAT signal in the occluded arm, with normalization to the ratio of the PAT signal in the control arm to account for any systemic hemodynamic changes.

Homeostatic model assessment for insulin resistance (HOMA-IR)

Time Frame: After 7 days of physical activity monitoring

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity using the homeostatic model assessment for insulin resistance (HOMA-IR). The HOMA-IR is calculated from the fasting insulin and glucose concentration.sensitivity and beta cell function. The following parameters are calculated: homeostatic model assessment for insulin resistance, whole-body insulin sensitivity index, insulinogenic index and the area under the curve for glucose and insulin.

Insulinogenic index

Time Frame: After 7 days of physical activity monitoring

An oral glucose tolerance test will be performed for assessment of beta cell function by calculation of the insulinogenic index. The insulinogenic index is calculated from both insulin and glucose concentrations.

Cardiac autonomic function

Time Frame: After 7 days of physical activity monitoring

Cardiac autonomic function will be operationalized as heart rate variability by means of continuous beat-to-beat heart rate signal measurements. time domain and frequency domain analysis of the R-R intervals will be performed

Systolic and Diastolic blood pressure

Time Frame: After 7 days of physical activity monitoring

Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer

Heart rate (HR)

Time Frame: After 7 days of physical activity monitoring

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of a heart rate monitor the HR is measured and averaged every ten seconds.

Arterial stiffness

Time Frame: After 7 days of physical activity monitoring

Arterial stiffness will be determined by pulse wave analysis (PWA) and pulse wave velocity (PWV) using SphygmoCor (v9; Atcor Medical).

Area under the curve of glucose and insulin concentrations

Time Frame: After 7 days of physical activity monitoring

An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of glucose and insulin concentrations

Oxygen uptake (VO2)

Time Frame: After 7 days of physical activity monitoring

Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VO2 is collected breath-by-breath and averaged every ten seconds.

Whole-body insulin sensitivity (WBISI)

Time Frame: After 7 days of physical activity monitoring

(fasting) glucose and (fasting) insulin levels measured during blood analysis from OGTT are used to calculate whole body-insulin sensitivity.

Secondary Outcomes

  • Exercise information(7 days)
  • Walking time(7 days)
  • Total calorie intake(7 days)
  • Modified fatigue impact scale (MFIS) questionnaire(After 7 days of physical activity monitoring)
  • Steps per day(7 days)
  • Sleeping time(7 days)
  • Macronutrient content(7 days)
  • RAND-36 Item Health Survey (RAND-36) questionnaire(After 7 days of physical activity monitoring)
  • Standing time(7 days)
  • 12-Item Multiple Sclerosis Walking Scale (MSWS-12) questionnaire(After 7 days of physical activity monitoring)
  • Sitting time(7 days)
  • Perceived stress scale (PSS) questionnaire(After 7 days of physical activity monitoring)

Study Sites (1)

Loading locations...

Similar Trials